Charles Schwab’s Lipocine LPCN Stock Holding History

Charles Schwab’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,941	Closed	-$15.9K	–	3645
2023 Q1	$15.9K	Hold	2,941	–	–	﹤0.01%	3523
2022 Q4	$19.2K	Hold	2,941	–	–	﹤0.01%	3507
2022 Q3	$23K	Hold	2,941	–	–	﹤0.01%	3468
2022 Q2	$41K	Hold	2,941	–	–	﹤0.01%	3421
2022 Q1	$69K	Hold	2,941	–	–	﹤0.01%	3478
2021 Q4	$50K	Buy	+2,941	New	+$54.6K	﹤0.01%	3515
2021 Q3	–	Sell	-2,153	Closed	-$52K	–	3531
2021 Q2	$52K	Hold	2,153	–	–	﹤0.01%	3361
2021 Q1	$56K	Buy	+2,153	New	+$62.1K	﹤0.01%	3429
2017 Q2	–	Sell	-1,535	Closed	-$102K	–	3122
2017 Q1	$102K	Hold	1,535	–	–	﹤0.01%	3015
2016 Q4	$97K	Hold	1,535	–	–	﹤0.01%	3043
2016 Q3	$117K	Hold	1,535	–	–	﹤0.01%	3001
2016 Q2	$80K	Buy	+1,535	New	+$238K	﹤0.01%	3070

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Charles Schwab's LPCN Position: Q2 2023 in Review

Charles Schwab sold out of Lipocine (LPCN) in Q2 2023, closing a stake of 2,941 shares — an estimated $15.9K sold.

Charles Schwab first reported a position in LPCN in Q2 2016 and held it in 12 quarters. The position peaked at $117K in Q3 2016. 24 funds tracked by Wall St. Rank hold LPCN as of Q2 2023.

Charles Schwab reported no remaining Lipocine position as of Q2 2023 after selling out during the quarter.
Charles Schwab sold 2,941 Lipocine shares in Q2 2023, an estimated $15.9K.
Charles Schwab first reported a position in Lipocine in Q2 2016 and held it in 12 quarters.
Charles Schwab's Lipocine position peaked at $117K in Q3 2016.
24 funds tracked by Wall St. Rank held Lipocine as of Q2 2023.

Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.